Genprex Inc GNPX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting
-
Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging
-
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
-
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy
-
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
Trading Information
- Previous Close Price
- $2.01
- Day Range
- $1.86–2.02
- 52-Week Range
- $1.71–158.18
- Bid/Ask
- $2.01 / $2.03
- Shares Outstanding
- 819,709.00
- Market Cap
- $1.66M
- Volume/Avg
- 10,480 / 273,343
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.genprex.com
Valuation
|
Metric
|
GNPX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.07 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
GNPX
Financial Strength
|
Metric
|
GNPX
|
|---|---|
Quick Ratio | 6.47 |
Current Ratio | 6.77 |
Interest Coverage | — |
Quick Ratio
GNPX
Profitability
|
Metric
|
GNPX
|
|---|---|
Return on Assets (Normalized) | −151.69% |
Return on Equity (Normalized) | −199.34% |
Return on Invested Capital (Normalized) | −198.09% |
Return on Assets
GNPX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#Gk^%$? | LOCK|>^ztt | $134B | |||
| Moderna Inc
MRNA
| LOCK|gg&<B>X | LOCK|&jL | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|KY?T$< | LOCK|n?^c% | $84B | |||
| argenx SE ADR
ARGX
| LOCK|KQ#k$c# | LOCK|gp$ | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|gx&dkC% | LOCK|M$ | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?G#m>? | LOCK|%Ndw | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<JHNZpm | LOCK|W$#r | $29B | |||
| Incyte Corp
INCY
| LOCK|b!qrCX | LOCK|r! | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|zGkLKt | LOCK|H<W | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|@&H<%M | LOCK|R<l | $14B |
United States